186 related articles for article (PubMed ID: 23045419)
1. Genetic defects in the cyp21a2 gene in heterozygous girls with premature adrenarche and adolescent females with hyperandrogenemia.
Neocleous V; Shammas C; Phedonos AP; Karaoli E; Kyriakou A; Toumba M; Phylactou LA; Skordis N
Georgian Med News; 2012 Sep; (210):40-7. PubMed ID: 23045419
[TBL] [Abstract][Full Text] [Related]
2. Genetic defects of the CYP21A2 gene in girls with premature adrenarche.
Skordis N; Shammas C; Phedonos AA; Kyriakou A; Toumba M; Neocleous V; Phylactou LA
J Endocrinol Invest; 2015 May; 38(5):535-9. PubMed ID: 25481255
[TBL] [Abstract][Full Text] [Related]
3. Hyperandrogenism in carriers of CYP21 mutations: the role of genotype.
Admoni O; Israel S; Lavi I; Gur M; Tenenbaum-Rakover Y
Clin Endocrinol (Oxf); 2006 Jun; 64(6):645-51. PubMed ID: 16712666
[TBL] [Abstract][Full Text] [Related]
4. Carriers of 21-hydroxylase deficiency are not at increased risk for hyperandrogenism.
Knochenhauer ES; Cortet-Rudelli C; Cunnigham RD; Conway-Myers BA; Dewailly D; Azziz R
J Clin Endocrinol Metab; 1997 Feb; 82(2):479-85. PubMed ID: 9024240
[TBL] [Abstract][Full Text] [Related]
5. Genetic screening of non-classic CAH females with hyperandrogenemia identifies a novel CYP11B1 gene mutation.
Shammas C; Byrou S; Phelan MM; Toumba M; Stylianou C; Skordis N; Neocleous V; Phylactou LA
Hormones (Athens); 2016 Apr; 15(2):235-242. PubMed ID: 27376426
[TBL] [Abstract][Full Text] [Related]
6. Phenotypic variability of hyperandrogenemia in females heterozygous for CYP21A2 mutations.
Neocleous V; Shammas C; Phedonos AA; Phylactou LA; Skordis N
Indian J Endocrinol Metab; 2014 Nov; 18(Suppl 1):S72-9. PubMed ID: 25538881
[TBL] [Abstract][Full Text] [Related]
7. The frequency of CYP 21 gene mutations in Turkish women with hyperandrogenism.
Kelestimur F; Everest H; Dundar M; Tanriverdi F; White C; Witchel SF
Exp Clin Endocrinol Diabetes; 2009 May; 117(5):205-8. PubMed ID: 19085698
[TBL] [Abstract][Full Text] [Related]
8. Clinical and hormonal characteristics in heterozygote carriers of congenital adrenal hyperplasia.
Guarnotta V; Niceta M; Bono M; Marchese S; Fabiano C; Indelicato S; Di Gaudio F; Garofalo P; Giordano C
J Steroid Biochem Mol Biol; 2020 Apr; 198():105554. PubMed ID: 31805392
[TBL] [Abstract][Full Text] [Related]
9. Premature pubarche in Mediterranean girls: high prevalence of heterozygous CYP21 mutation carriers.
Paris F; Tardy V; Chalançon A; Picot MC; Morel Y; Sultan C
Gynecol Endocrinol; 2010 May; 26(5):319-24. PubMed ID: 20059433
[TBL] [Abstract][Full Text] [Related]
10. Differences in hormonal levels between heterozygous
Silva RS; Carvalho B; Pedro J; Castro-Correia C; Carvalho D; Carvalho F; Fontoura M
Arch Endocrinol Metab; 2022 Apr; 66(2):168-175. PubMed ID: 35289513
[TBL] [Abstract][Full Text] [Related]
11. Relationship of CYP21A2 genotype and serum 17-hydroxyprogesterone and cortisol levels in a large cohort of Italian children with premature pubarche.
Ghizzoni L; Cappa M; Vottero A; Ubertini G; Carta D; Di Iorgi N; Gasco V; Marchesi M; Raggi V; Ibba A; Napoli F; Massimi A; Maghnie M; Loche S; Porzio O
Eur J Endocrinol; 2011 Aug; 165(2):307-14. PubMed ID: 21646284
[TBL] [Abstract][Full Text] [Related]
12. Prevalence and Clinical Outcome of CYP21A2 Gene Mutations in Patients with Nonfunctional Adrenal Incidentalomas.
Kiedrowicz B; Binczak-Kuleta A; Lubikowski J; Koziolek M; Andrysiak-Mamos E; Ostanek-Panka M; Ciechanowicz A; Syrenicz A
Horm Metab Res; 2015 Aug; 47(9):662-7. PubMed ID: 25970792
[TBL] [Abstract][Full Text] [Related]
13. Rare mutations in the CYP21A2 gene detected in congenital adrenal hyperplasia.
Neocleous V; Ioannou YS; Bartsota M; Costi C; Skordis N; Phylactou LA
Clin Biochem; 2009 Sep; 42(13-14):1363-7. PubMed ID: 19501079
[TBL] [Abstract][Full Text] [Related]
14. A rational, non-radioactive strategy for the molecular diagnosis of congenital adrenal hyperplasia due to 21-hydroxylase deficiency.
Coeli-Lacchini FB; Turatti W; Elias PC; Elias LL; Martinelli CE; Moreira AC; Antonini SR; de Castro M
Gene; 2013 Sep; 526(2):239-45. PubMed ID: 23570880
[TBL] [Abstract][Full Text] [Related]
15. Hyperandrogenism and manifesting heterozygotes for 21-hydroxylase deficiency.
Witchel SF; Lee PA; Suda-Hartman M; Hoffman EP
Biochem Mol Med; 1997 Dec; 62(2):151-8. PubMed ID: 9441866
[TBL] [Abstract][Full Text] [Related]
16. Detected heterozygotes during the molecular analysis of the common CYP21A2 point mutations in Macedonian patients with congenital adrenal hyperplasia and their relatives.
Anastasovska V; Kocova M
Prilozi; 2010; 31(2):71-82. PubMed ID: 21258279
[TBL] [Abstract][Full Text] [Related]
17. A rare CYP21A2 mutation in a congenital adrenal hyperplasia kindred displaying genotype-phenotype nonconcordance.
Khattab A; Yuen T; Al-Malki S; Yau M; Kazmi D; Sun L; Harbison M; Haider S; Zaidi M; New MI
Ann N Y Acad Sci; 2016 Jan; 1364(1):5-10. PubMed ID: 26291314
[TBL] [Abstract][Full Text] [Related]
18. 17-Hydroxyprogesterone Response to Standard Dose Synacthen Stimulation Test in
Polat S; Arslan YK
J Clin Res Pediatr Endocrinol; 2022 Mar; 14(1):56-68. PubMed ID: 34743977
[TBL] [Abstract][Full Text] [Related]
19. High carrier frequency of 21-hydroxylase deficiency in Cyprus.
Phedonos AA; Shammas C; Skordis N; Kyriakides TC; Neocleous V; Phylactou LA
Clin Genet; 2013 Dec; 84(6):585-8. PubMed ID: 23600966
[TBL] [Abstract][Full Text] [Related]
20. The spectrum of clinical, hormonal and molecular findings in 280 individuals with nonclassical congenital adrenal hyperplasia caused by mutations of the CYP21A2 gene.
Livadas S; Dracopoulou M; Dastamani A; Sertedaki A; Maniati-Christidi M; Magiakou AM; Kanaka-Gantenbein C; Chrousos GP; Dacou-Voutetakis C
Clin Endocrinol (Oxf); 2015 Apr; 82(4):543-9. PubMed ID: 25041270
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
